

Binding and Structural Properties of DNA Aptamers with VEGF-A-Mimic Activity

Toru Yoshitomi,¹ Misako Hayashi,¹ Takumi Oguro,¹ Keiko Kimura,¹ Fumiya Wayama,¹ Hitoshi Furusho,² and Keitaro Yoshimoto^{1,3}

¹Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo 153-8902, Japan; ²Chemical General Division, Nissan Chemical Industries, 2-10-2 Tsuboi-nishi, Funabashi, Chiba 274-8507, Japan; ³JST, PRESTO, The University of Tokyo, Komaba 3-8-1, Meguro-ku, Tokyo 153-8902, Japan

Vascular endothelial growth factors (VEGFs) are hypoxia-inducible secreted proteins to promote angiogenesis, in which VEGF-A is an important molecule that binds and activates VEGF receptor-1 (VEGFR-1) and VEGFR-2. In this study, two DNA aptamers, Apt01 and Apt02, were successfully isolated by alternating consecutive systematic evolution of ligands by exponential enrichment (SELEX) against VEGFR-1 and -2 using deep sequencing analysis in an early selection round. Their binding affinities for VEGFR-2 were lower than that of VEGFR-1, which is similar to that of VEGF-A. Structural analyses with the measurements of circular dichroism spectra and ultraviolet melting curve showed that Apt01 possessed the stem-loop structure in the molecule, whereas Apt02 formed G-quadruplex structures. In addition, Apt02 accelerated a tube formation of human umbilical vein endothelial cells faster than Apt01, which was affected by difference of binding affinity and nuclease resistance due to G-quadruplex structures. These results demonstrated that Apt02 might have a potential to function as an alternative to VEGF-A.

INTRODUCTION

Vascular endothelial growth factors (VEGFs) are hypoxia-inducible secreted proteins to promote angiogenesis.¹ Among them, VEGF-A is the major contributor to physiological and pathological angiogenesis.² VEGF-A binds and activates vascular endothelial growth factor receptor-1 (VEGFR-1) and VEGFR-2, which are members of the family of receptor tyrosine kinases on endothelial cells. VEGFR-1 and -2 share 43.2% overall sequence similarity.² The sequences of their extracellular domains are 33.3% similar, and those of their kinase domains are the most similar (70.1%).² VEGF-A binds to VEGFR-1 with at least 10-fold higher affinity (dissociation constant [K_D]: 2–10 pM) than VEGFR-2.³ However, most studies showed that VEGFR-2 is the functional receptor for VEGF-A, which transmits signals that regulate the proliferation and differentiation of endothelial cells. In contrast, there is controversy about the importance of VEGFR-1 in vascular remodeling, macrophage function, inflammatory diseases, and metastasis of cancer.^{3,4}

Recently, VEGF-A has been used as one of the essential molecules for induction of differentiation to endothelial^{5,6} and cardiac myocyte⁷

cells from human induced pluripotent stem cells and embryonic stem cells. However, intrinsic drawbacks of recombinant VEGF-A, such as low stability, lot-to-lot variation, and the high cost of production, have been serious problems for use of stem cell-based regenerative therapy and relevant basic research. Therefore, replacing expensive and unstable recombinant protein such as VEGFs with synthetic alternatives is important in the biomedical fields, especially stem cell-based regenerative medicines.^{8–10}

DNA aptamers are single-stranded oligonucleotides with high affinity to specific targets, such as proteins¹¹ and entire cells.¹² DNA aptamers offer several specific advantages owing to their low cost of production and high thermal stability.¹³ These features are beneficial for applications as therapeutic agents. DNA aptamers are isolated by systematic evolution of ligands by exponential enrichment (SELEX).^{14,15} The DNA aptamers that bind VEGFR-1 and -2 may serve as the alternatives to VEGF-A. However, compared with SELEX to isolate aptamers that bind to a single target, the consecutive SELEX against multiple target molecules requires numerous selection rounds.¹⁶ In addition, in the course of SELEX with multiple rounds, selective pressure shifts the sequence of aptamers from the one with high affinity to the one that is amplified with higher efficiency.¹⁶ This PCR amplification bias tends to favor shorter as well as structurally unstable sequences.¹⁶ Therefore, rapid acquisition of aptamer candidates within fewer selection rounds is desired for avoiding PCR amplification bias.^{12,17}

To obtain DNA aptamers with function similar to VEGF-A, in this study, we conducted alternating consecutive SELEX of DNA aptamers against double targets, VEGFR-1 and -2, using deep sequencing analysis with next generation sequencing (NGS).

RESULTS AND DISCUSSION

As an initial pool, 70-mer single-stranded oligodeoxynucleotides (ssODNs) containing a random 34-mer sequence with flanking

Received 20 March 2019; accepted 23 December 2019;
<https://doi.org/10.1016/j.omtn.2019.12.034>

Correspondence: Keitaro Yoshimoto, Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo 153-8902, Japan.

E-mail: ckeitaro@mail.ecc.u-tokyo.ac.jp






Figure 2. Secondary Structures of the Aptamers.

(A and B) Secondary structures of (A) Apt01 and (B) Apt02 estimated using m-fold. G-rich sequences were included in Apt02, but not in Apt01. G scores of Apt01 and Apt02 estimated by QGRS mapper were 0 and 20, respectively. G-quadruplex-forming guanine residues in the Apt02 sequence, from 13G to 33G, were estimated by QGRS mapper and indicated as red-edged circles.

(10 mM Tris with 1 mM EDTA [pH 8.0]; Cat. No. 316-90025; Nippon Gene) at 95°C for 10 min, and the ODNs in the supernatant were PCR amplified using PrimeSTAR (Cat. No. R010A; Takara Bio, Japan) with the primer set 5'-GCC TGT TGT GAG CCT CCT-3' and 5'-biotin-GGG AGA CAA GAA TAA GCG-3'. Thermal cycling was performed by incubating the reactions at 94°C for 3 min,

of agonistic aptamer against VEGFR-1 and -2 to induce tube formation of HUVECs.

In conclusion, nuclease-resistant G-quadruplex DNA aptamer with VEGF A-mimic activity, Apt02, was isolated by alternating consecutive SELEX against VEGFR-1 and -2 using deep sequencing analysis, which might have a potential to function as the alternative to VEGF-A.

MATERIALS AND METHODS

In Vitro Selection of DNA Aptamers against VEGFR-1 and VEGFR-2

Preparation of MBs

VEGFR-1 Fc chimera (Cat. No. 321-FL-055; R&D Systems, USA), VEGFR-2 Fc chimera (Cat. No. 357-KD-050; R&D Systems, USA), and human IgG-Fc fragment (IgG-Fc) (Cat. No. P80-104-35; Bethyl Laboratories, USA) were immobilized onto protein A-coated MBs (Cat. No. 88845; Thermo Fisher Scientific, USA), according to the manufacturer's instructions. Human albumin (HA; recombinant expressed in plants; Cat. No. 018-21541; Wako Pure Chemical Industries, Japan) was used as a blocking reagent. MBs on which HA and VEGFR-1, HA and VEGFR-2, or HA and IgG-Fc were immobilized were prepared, named MB1, MB2, and Fc-MB, respectively.

Collection and Amplification of Target-Binding ODNs

Seventy-mer ssODNs containing a random 34-mer sequence with flanking primer regions were used. The sequence of ssODNs with random region (N_{34}) is as follows: 5'-GCC TGT TGT GAG CCT CCT N_{34} CGC TTA TTC TTG TCT CCC-3' (Nihon Gene Research Laboratories, Japan). The ODN library was first incubated with MB1 in PBS-E buffer (PBS containing 2 mM EDTA and 0.1% w/w HA) for 30 min, and then MB1 was washed with PBS-E three times and collected using a magnet. The ssODNs bound to MB1 were eluted by heating MB1 in TE buffer

followed by 25 cycles at 94°C for 30 s, 66°C for 5 s, and 72°C for 60 s.

Purification of PCR Amplicons

After analyzing the PCR amplicons using polyacrylamide gel electrophoresis, ssODNs were isolated by incubating the PCR amplicons with streptavidin-coated MBs (Cat. No. 5325; JSR Life Sciences Corporation, Japan) and eluting the non-biotinylated strand with elution buffer (0.1N NaOH and 0.1 M NaCl). Then, the buffer used to elute ssODNs was replaced with storage buffer (TBS; 20 mM Tris, 1 mM EDTA, 200 mM NaCl, 0.1% w/w Tween 20 [pH 7.4]) using an Xpress Micro Dialyzer (Cat. No. 40071-X280; Scienova, Germany), followed by the next selection round as described above.

Alternating Consecutive Selection against MB1 and MB2

The three cycles of consecutive selection against MB1 and MB2 are demonstrated as depicted in Figure S1 (three alternating rounds against MB1 and MB2, six rounds total). The details of the experimental conditions for each selection round are summarized in Table S1.

NGS and Frequency Analysis

Preparation of Tagged ODN Samples

To obtain tagged ODN samples for emulsion PCR, we amplified the PCR amplicons obtained at each round using tagged primer sets with the same sequence of the 18-mer primers used in the previous section (underlined) with barcode region (X_{10}) (forward primer: 5'-CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG XXX XXX XXX XGA TGC CTG TTG TGA GCC TCC T-3', reverse primer: 5'-CCT CTC TAT GGG CAG TCG GTG ATG GGA GAC AAG AAT AAG CG-3'). Thermal cycling was performed by incubating the reactions at 94°C for 3 min followed by 15 cycles at 94°C for 30 s, 66°C for 5 s, and 72°C for 60 s. The sequences of the barcode regions (X_{10}) were as follows: 5'-CAG AAG GAA C-3' (ID 005; for cycle 1-R1), 5'-CTG CAA GTT C-3' (ID 006; for cycle 1-R2), 5'-TTC GTG ATT C-3' (ID 007; for cycle 2-R1), 5'-TTC CGA TAA C-3'




Figure 3. Circular Dichroism (CD) Spectra of the Aptamers in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, and 1.5 mM NaH₂PO₄ [pH 7.4]). CD spectrum of Apt02 (red) showed negative and positive peaks at approximately 240 and 260 nm, respectively, which corresponded with the spectrum of parallel-type G-quadruplexes. On the other hand, Apt01 (black) showed negative and positive peaks at approximately 250 and 280 nm, respectively, which corresponded with the spectrum of the typical double-stranded oligodeoxynucleotides.

(ID 008; for cycle 2-R2), 5'-TGA GCG GAA C-3' (ID 009; for cycle 3-R1), and 5'-CTG ACC GAA C-3' (ID 010; for cycle 3-R2).

Purification of Tagged ODN Samples

PCR products generated using the tagged primer sets described above were PCR amplified using short primer sets (forward primer 5'-CCA TCT CAT CCC TGC GTG TC-3'; reverse primer 5'-CCT CTC TAT GGG CAG TCG GT-3') as follows: 94°C for 3 min followed by five cycles at 94°C for 30 s, 50°C for 30 s, and 68°C for 30 s. After removing the short primer ODNs and other PCR reagents using the Fast Gene Gel/PCR Extraction Kit (Cat. No. FG-91202; Nippon Genetics, Japan), purified PCR products were obtained (5'-CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG XXX XXX XXX XGA TGC CTG TTG TGA GCC TCC T-N₃₄-CGC TTA TTC TTG TCT CCC ATC ACC GAC TGC CCA TAG AGA GG-3'). Polyacrylamide gel electrophoresis was performed to determine the yields and purities of the amplicons.

Emulsion PCR and NGS

Emulsion PCR was performed to prepare monoclonal amplicon-modified beads using Ion OneTouch 2 system (Life Technologies, CA, USA) with a mixture containing equal amounts of the six tagged ODN samples as a template. After bead preparation, the Ion PGM System (Life Technologies, CA, USA) was employed to sequence the beads using an Ion 314 Chip. Emulsion PCR, bead preparation, and sequencing were performed according to the Ion PGM user guides (Publication Number MAN0007220, Rev. 5.0 and MAN0007273, Rev. 3.0, respectively) with the Ion PGM Template OT2 200 Kit, Ion PGM Sequencing 200 Kit v.2, and Ion 314 Chip Kit v.2 (Life Technologies, CA, USA).




Figure 4. Ultraviolet (UV) Melting Profiles of the Aptamers

(A–D) The UV melting profiles of aptamers in 10 mM phosphate buffer containing 100 mM NaCl (black colored plots) or in 10 mM phosphate buffer containing 100 mM KCl (red colored plots): (A) Apt01 at 295 nm, (B) Apt02 at 295 nm, (C) Apt01 at 260 nm, and (D) Apt02 at 260 nm. The melting profiles normalized by the absorbance at 5°C are shown. The hypochromic transition was observed only in the UV melting curve of Apt02 at 295 nm in 10 mM phosphate buffer containing 100 mM KCl, indicating that Apt02 possessed G-quadruplex. In the UV melting curves of Apt01 at 260 nm, hyperchromic transitions with a single sigmoidal shape, indicating that Apt01 possessed the stem-loop structure in the molecule.

Deep Sequence Analysis

All sequencing data for each round were exported as FASTAQ files from the Ion PGM System. Changes in the abundance ratio of each sequence were calculated and compared by Sequence Analyzer (LifeMatics, Japan) that contains the CD-HIT-EST³² algorithm for sequence clustering. As shown in Figure S1, using Sequence Analyzer v.1.0.9, sequence acquisition of each round was carried out through the following parameters: quality criteria: 15, maximum low-quality element: 5, length of variable: 32–37. After sequence acquisition, homology clustering was carried out (similarity criteria: 90) and the two enriched sequences, which increase their avoidance ratios with increase in round number, were successfully picked up by “compare window” of Sequence Analyzer. In these processes, sequences with their primers were used.

Measurement of SPR

To determine the binding affinities of aptamers for VEGFR-1 and VEGFR-2, we used a BIAcore X (GE Healthcare, USA) to perform binding analyses at 25°C. Because the sensor chip surface was not regenerated with a regeneration buffer, single-cycle kinetics analyses, which run a series of analyte concentrations in one cycle




Figure 5. Stability of the Obtained Aptamer, Apt01 and Apt02, during Incubation in Medium 200PRF with LSGS Kit for 24 h, as Determined by Denaturing Urea Polyacrylamide Gel Electrophoresis (PAGE)

(A) Representative images of denaturing urea PAGE. Bands of intact aptamers are indicated with arrows. (B) Graphical representation of PAGE results. The fraction of intact aptamers (relative to the sample without incubation in Medium 200 with LSGS kit) was plotted as a function of time. Stained DNA was imaged with Digi-Gel Shot (Takara Bio) and quantified using ImageJ software package. Almost Apt01 was degraded in cell culture medium even at 4 h, whereas even at 24 h, 86% of Apt02 remained in the culture medium. The bar graphs represent means \pm standard error for three independent experiments.

with no regeneration between sample injections, were used in this study.

In the case of VEGFR-2, DNA aptamer-immobilized sensor surface was constructed, and a concentration series of VEGFR-2 was injected. To construct a DNA aptamer-immobilized sensor surface, a biotinylated ODN fragment (capture-ODN, 5'-dT₄₄-biotin-3') was first modified on a Sensor Chip SA (GE Healthcare, USA) through the avidin-biotin interaction by injecting the capture-ODN solution for 6 min at a flow rate of 5 μ L/min in DPBST containing 137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.5 mM KH₂PO₄, and 0.05% Tween 20 (pH 7.4). Aptamer candidates (5'-dA₃₀-dT₅-Apt01-3' and 5'-dA₃₀-dT₅-Apt02-3') that hybridized to the capture-ODN were immobilized by hybridization between dA₃₀ and dT₃₀ that was accomplished by injecting the DNA solution for 3.5 min, at a flow rate of 20 μ L/min in DPBST. A concentration series of VEGFR-2 in DPBST was injected at a flow rate of 30 μ L/min for 1 min, and dissociation was monitored for about 1.5 min using flowing running buffer (DPBST) (30 μ L/min). As a reference, 5'-dA₃₀-dT₅-3' was hybridized to the capture-ODN immobilized surface, and its sensorgram was subtracted from those of measuring flow cells.

In the case of VEGFR-1, strong non-specific binding of VEGFR-1 on the flow-cell and sensor surfaces was observed. Thus, VEGFR-1-immobilized sensor surface was constructed, and a concentration series of DNA aptamer was injected. To construct a VEGFR-1-immobilized sensor surface, we injected 50 mg/mL VEGFR-1 in acetic acid buffer onto Sensor Chip CM5 (GE Healthcare, USA) for 7 min at a flow rate of 5 μ L/min in HBS-EP buffer (GE Healthcare, USA) containing 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.005% Surfactant P20 (pH 7.4). A concentration series of VEGFR-1 in HBS-EP was injected at a flow rate of 30 μ L/min for 1 min, and dissociation was monitored for about 1.5 min using flowing running buffer (HBS-EP) (30 μ L/min). The data were fitted with a 1:1 binding model using

the BIAevaluation software version 4.1.1 (GE Healthcare, USA), and the K_D values were determined using single-cycle kinetics.

Prediction of the Secondary and G-Quadruplex Structures of DNA Aptamers

Secondary structures of Apt01 and Apt02 were predicted using m-fold (25°C, 1 M [Na⁺]). Estimation of G-quadruplex formation by these aptamers was performed using QGSR mapper (maximum length, 35; minimum group, 2; loop size, 0–36).

Measurement of CD

CD analysis of the obtained aptamers was performed using 4 μ M ODNs in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, and 1.5 mM NaH₂PO₄ [pH 7.4]). The ODN samples were denatured at 95°C before analysis and cooled slowly to room temperature. Their CD spectra were measured using a J-725 CD Spectrometer (JASCO Corporation, Japan) with a 1-cm path-length quartz cuvette using a constant flow of dry nitrogen. Scans were performed twice from 220 to 350 nm at 500 nm/min with a 1-s response time, 0.5-nm pitch, 1-nm bandwidth, and 100-millidegree sensitivity. The CD spectrum of PBS (blank) was measured in the same manner and subtracted from the collected data.

Measurement of UV Melting Curve

UV absorbance versus temperature profiles (melting curves) was measured for each aptamer at two wavelengths, 260 and 295 nm, by TMSPC-8 with a SHIMAZU UV-2450 spectrophotometer. ODNs were prepared at 4 μ M in phosphate buffer containing NaCl (10 mM Na₂HPO₄, 10 mM NaH₂PO₄, and 100 mM NaCl [pH 7.4]) or phosphate buffer containing KCl (10 mM Na₂HPO₄, 10 mM NaH₂PO₄, and 100 mM KCl [pH 7.4]). These samples were then heat annealed to 90°C and allowed to slowly cool to 4°C over a period of several hours. Then 110 μ L of a sample was transferred to a 1-cm path-length quartz cuvette and covered with a layer of 30 μ L liquid paraffin. It was heated to 95°C and cooled to room temperature at 0.5°C/min, with data collection occurring every 0.5 min on the annealing and melting steps.

HUVEC Culture

HUVECs (HUVEC-2) derived from single donors were obtained from Corning (San Jose, CA, USA). Medium 200 phenol red free (PRF) (Cat No. M200PRF500) and Low Serum Growth Supplement kit (Cat. No. S-003-K; GIBCO) were obtained from Thermo Scientific (MA, USA). HUVEC-2 was cultured in Medium 200PRF supplemented with low serum growth supplement (LSGS). The cells were incubated in a 37°C, 5% CO₂/95% air, humidified cell culture incubator. The media were changed every 5 days. When confluent or for seeding on different structures, cells were detached with trypsin/EDTA, and then trypsin neutralization solution was added. Cells were centrifuged at 200 \times g for 5 min and dispersed in growth medium.

In Vitro Tube Formation Assay

In brief, after defrosting on ice, BD Matrigel Matrix (~10 mg/mL; Cat. No. 354234, Corning, NY, USA) was added to the pre-cooled




Figure 6. In Vitro Tube Formation Assay Using Human Umbilical Vein Endothelial Cells (HUVECs) on a Three-Dimensional Gel Consisting of Diluted Matrigel

The cells were treated with Apt01 (10 μ M), Apt02 (10 μ M), or VEGF165 (10 ng/mL, 0.26 nM) for 24 h. (A) Representative images of tube formation of HUVECs on Matrigel, which are treated by aptamers or VEGF165. Scale bars, 1 mm. (B) Time course of mesh number in the images of the HUVEC networks at 4, 7, and 24 h. Error bars represent standard deviation of the mean ($n = 3$ plots). (C–E) Boxplot showing mesh number in the images of the HUVEC networks at (C) 4, (D) 7, and (E) 24 h ($n = 3$ plots). * $p < 0.05$ as compared with control; ** $p < 0.05$ as compared with Apt01.

24-well plates at 298 μ L/well followed by incubation for 1 h at 37°C. HUVECs were trypsinized, pelleted by low-speed centrifugation, and suspended in Medium 200PRF supplemented with LSGS. HUVECs (1.1×10^5 cells/well) were placed into 24-well flat-bottomed plates pre-coated with Matrigel and then incubated with aptamers (10 μ M) or VEGF165 (Recombinant Human VEGF 165 Protein, Cat. No. 293-VE [R&D Systems, USA]; 10 ng/mL, 0.26 nM) for 24 h. In the experiment of dose dependency, the

Apt02 concentration of more than 10 μ M showed the significant difference from control group (data not shown). After incubation, cell tube or network formation was observed using a phase-contrast microscope (IX51S8F-3; Olympus, Japan). The number of mesh-like circles was manually counted.

Stability Assay of Aptamer in Cultured Medium

The aptamers (0.4 μ M) were incubated in Medium 200PRF supplemented with LSGS for 0.5, 1, 2, 3, 4, 7, or 24 h at 37°C, followed by heating sample for 20 min at 80°C for inactivation of nucleases. Samples were analyzed by denaturing PAGE using a 10% polyacrylamide/urea gel and stained with Lonza GelStar Nucleic Acid Gel Stain (Cat. No. 50535; Lonza). Stained DNA was imaged with Digi-Gel Shot (Takara Bio) and quantified using ImageJ software package. The fraction of intact aptamers was normalized to the DNA sample without incubation at each time point.

Statistical Analysis

All values are expressed as mean \pm standard error. Statistical difference was analyzed by Kaleida Graph 4.1 version 4.13 (Synergy Software, USA). All one-way analyses of variance (ANOVAs) were performed with one-way ANOVA tests followed by post hoc Tukey's honestly significantly different (HSD) test. Differences with a p value < 0.05 were considered statistically significant.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.omtn.2019.12.034>.

AUTHOR CONTRIBUTIONS

Conception and Design: K.Y.; Acquisition of Data: M.H., T.O., K.K., and F.W.; Analysis and Interpretation of Data: T.Y., M.H., T.O., K.K., F.W., and K.Y.; Writing – Review and/or Revision of the Manuscript: T.Y. and K.Y.; Administrative, Technical, or Material Support: H.F.; Study Supervision: K.Y.; Equal Contribution: M.H. and T.O.

CONFLICTS OF INTEREST

The authors declare no competing interests.

ACKNOWLEDGMENTS

This study is part of a collaborative research project between Nissan Chemical Industries, Ltd. (Japan) and the Yoshimoto research group at The University of Tokyo (Japan), and was partly funded by PRESTO-JST (grant number JPMJPR16FB), JST-SCORE (Japan), JSPS KAKENHI (grant number 18H02002), and Iketani Science and Technology Foundation (Japan).

REFERENCES

- Olsson, A.K., Dimberg, A., Kreuger, J., and Claesson-Welsh, L. (2006). VEGF receptor signalling - in control of vascular function. *Nat. Rev. Mol. Cell Biol.* 7, 359–371.
- Rahimi, N. (2006). VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. *Front. Biosci.* 11, 818–829.
- Shibuya, M. (2006). Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. *Angiogenesis* 9, 225–230, discussion 231.

4. Dias, S., Hattori, K., Zhu, Z., Heissig, B., Choy, M., Lane, W., Wu, Y., Chadburn, A., Hyjek, E., Gill, M., et al. (2000). Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. *J. Clin. Invest.* *106*, 511–521.
5. Nourse, M.B., Halpin, D.E., Scatena, M., Mortisen, D.J., Tulloch, N.L., Hauch, K.D., Torok-Storb, B., Ratner, B.D., Pabon, L., and Murry, C.E. (2010). VEGF induces differentiation of functional endothelium from human embryonic stem cells: implications for tissue engineering. *Arterioscler. Thromb. Vasc. Biol.* *30*, 80–89.
6. Ikuno, T., Masumoto, H., Yamamizu, K., Yoshioka, M., Minakata, K., Ikeda, T., et al. (2017). Efficient and robust differentiation of endothelial cells from human induced pluripotent stem cells via lineage control with VEGF and cyclic AMP. *PLoS ONE* *12*, e0173271.
7. Ye, L., Zhang, S., Greder, L., Dutton, J., Keirstead, S.A., Lepley, M., Zhang, L., Kaufman, D., and Zhang, J. (2013). Effective cardiac myocyte differentiation of human induced pluripotent stem cells requires VEGF. *PLoS ONE* *8*, e53764.
8. Ramaswamy, V., Monsalve, A., Sautina, L., Segal, M.S., Dobson, J., and Allen, J.B. (2015). DNA Aptamer Assembly as a Vascular Endothelial Growth Factor Receptor Agonist. *Nucleic Acid Ther.* *25*, 227–234.
9. Ueki, R., Ueki, A., Kanda, N., and Sando, S. (2016). Oligonucleotide-Based Mimetics of Hepatocyte Growth Factor. *Angew. Chem. Int. Ed. Engl.* *55*, 579–582.
10. Ueki, R., Atsuta, S., Ueki, A., Hoshiyama, J., Li, J., Hayashi, Y., and Sando, S. (2019). DNA aptamer assemblies as fibroblast growth factor mimics and their application in stem cell culture. *Chem. Commun. (Camb.)* *55*, 2672–2675.
11. Bock, L.C., Griffin, L.C., Latham, J.A., Vermaas, E.H., and Toole, J.J. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. *Nature* *355*, 564–566.
12. Saito, S., Hirose, K., Tsuchida, M., Wakui, K., Yoshimoto, K., Nishiyama, Y., and Shibukawa, M. (2016). Rapid acquisition of high-affinity DNA aptamer motifs recognizing microbial cell surfaces using polymer-enhanced capillary transient isotachopheresis. *Chem. Commun. (Camb.)* *52*, 461–464.
13. Kristian, S.A., Hwang, J.H., Hall, B., Leire, E., Iacomini, J., Old, R., Galili, U., Roberts, C., Mullis, K.B., Westby, M., and Nizet, V. (2015). Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer. *J. Mol. Med. (Berl.)* *93*, 619–631.
14. Ellington, A.D., and Szostak, J.W. (1990). In vitro selection of RNA molecules that bind specific ligands. *Nature* *346*, 818–822.
15. Tuerk, C., and Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science* *249*, 505–510.
16. Blind, M., and Blank, M. (2015). Aptamer Selection Technology and Recent Advances. *Mol. Ther. Nucleic Acids* *4*, e223.
17. Acinas, S.G., Sarma-Rupavarm, R., Klepac-Ceraj, V., and Polz, M.F. (2005). PCR-induced sequence artifacts and bias: insights from comparison of two 16S rRNA clone libraries constructed from the same sample. *Appl. Environ. Microbiol.* *71*, 8966–8969.
18. Metzker, M.L. (2010). Sequencing technologies—the next generation. *Nat. Rev. Genet.* *11*, 31–46.
19. Mac Gabhann, F., and Popel, A.S. (2007). Dimerization of VEGF receptors and implications for signal transduction: a computational study. *Biophys. Chem.* *128*, 125–139.
20. Markovic-Mueller, S., Stutfeld, E., Asthana, M., Weinert, T., Bliven, S., Goldie, K.N., Kisko, K., Capitani, G., and Ballmer-Hofer, K. (2017). Structure of the Full-length VEGFR-1 Extracellular Domain in Complex with VEGF-A. *Structure* *25*, 341–352.
21. Zuker, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res.* *31*, 3406–3415.
22. Kikin, O., D'Antonio, L., and Bagga, P.S. (2006). QGRS Mapper: a web-based server for predicting G-quadruplexes in nucleotide sequences. *Nucleic Acids Res.* *34*, W676–W682.
23. Tóthová, P., Krafčíková, P., and Víglaský, V. (2014). Formation of highly ordered multimers in G-quadruplexes. *Biochemistry* *53*, 7013–7027.
24. Masiero, S., Trotta, R., Pieraccini, S., De Tito, S., Perone, R., Randazzo, A., and Spada, G.P. (2010). A non-empirical chromophoric interpretation of CD spectra of DNA G-quadruplex structures. *Org. Biomol. Chem.* *8*, 2683–2692.
25. Ivanov, V.I., Minchenkova, L.E., Schyolkina, A.K., and Poletayev, A.I. (1973). Different conformations of double-stranded nucleic acid in solution as revealed by circular dichroism. *Biopolymers* *12*, 89–110.
26. Mergny, J.L., Phan, A.T., and Lacroix, L. (1998). Following G-quartet formation by UV-spectroscopy. *FEBS Lett.* *435*, 74–78.
27. Yang, X., Liu, D., Lu, P., Zhang, Y., and Yu, C. (2010). Nucleic acid G-quadruplex based label-free fluorescence turn-on potassium selective sensing. *Analyst (Lond.)* *135*, 2074–2078.
28. Orpana, A.K., Ho, T.H., and Stenman, J. (2012). Multiple heat pulses during PCR extension enabling amplification of GC-rich sequences and reducing amplification bias. *Anal. Chem.* *84*, 2081–2087.
29. Bochman, M.L., Paeschke, K., and Zakian, V.A. (2012). DNA secondary structures: stability and function of G-quadruplex structures. *Nat. Rev. Genet.* *13*, 770–780.
30. Tucker, W.O., Shum, K.T., and Tanner, J.A. (2012). G-quadruplex DNA aptamers and their ligands: structure, function and application. *Curr. Pharm. Des.* *18*, 2014–2026.
31. Sun, Q., Zhou, J., Zhang, Z., Guo, M., Liang, J., Zhou, F., Long, J., Zhang, W., Yin, F., Cai, H., et al. (2014). Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. *Cancer Biol. Ther.* *15*, 1635–1645.
32. Li, W., and Godzik, A. (2006). Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. *Bioinformatics* *22*, 1658–1659.

OMTN, Volume 19

Supplemental Information

Binding and Structural Properties of DNA Aptamers with VEGF-A-Mimic Activity

Toru Yoshitomi, Misako Hayashi, Takumi Oguro, Keiko Kimura, Fumiya Wayama, Hitoshi Furusho, and Keitaro Yoshimoto

1 **Supporting information**

2

3

4 **Binding and structural properties of DNA aptamers with VEGF-A-**
5 **mimic activity**

6

7 Toru Yoshitomi¹, Misako Hayashi¹, Takumi Oguro¹, Keiko Kimura¹, Fumiya Wayama¹,
8 Hitoshi Furusho², and Keitaro Yoshimoto^{*,1,3}

9

10 ¹Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo,
11 Komaba 3-8-1, Meguro-ku, Tokyo 153-8902, Japan

12 ²Chemical General Division, Nissan Chemical Industries, Ltd., 2-10-2 Tsuboi-nishi, Funabashi,
13 Chiba 274-8507, Japan

14 ³JST, PRESTO, The University of Tokyo, Komaba 3-8-1, Meguro, Tokyo 153-8902, Japan

15

16 *Corresponding author: Keitaro Yoshimoto, Ph.D., Department of Life Sciences, Graduate
17 School of Arts and Sciences, The University of Tokyo, Komaba 3-8-1, Meguro, Tokyo 153-
18 8902, Japan

19

20 Phone and FAX: +81-3-5454-6580

21 E-mail: ckeitaro@mail.ecc.u-tokyo.ac.jp

22

1

Table S1. *In vitro* selection conditions

Selection cycle	round	MB	[MB] (μg)	[ssODN] (μM)	Incubation volume (μL)	Number of washes	Washing volume (μL)
1	1	MB1		0.64			
	2	MB2		0.25			
2	3	MB1	8.5	0.28	20	3	200
	4	MB2		0.15			
3	5	MB1		0.17			
	6	MB2		0.21			

2

Table S2. Abundance distribution of Apt01 families (5'-XGTCGTGTTTGTGTTGTTTTCATTTTTGCGGCXXX-3') at each round.

Selection cycle	target	Number of total reads	Sequence (5' to 3')	Ranking	Counting number	Total counting number	Total abundance ratio (%)
1	VEGFR-1	32,984	Not found	-	ND	ND	0
	VEGFR-2	52,245	GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	5 th	3	3	0.06
2	VEGFR-1	32,173	GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	2 nd	185	287	0.892
			GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	5 th	90		
			GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	42 nd (tie)	6		
			GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	42 nd (tie)	6		
			GTCGTGTTGTTGTTGTTTTCATTTTTGTGGCC	757 th (tie)	1		
			GTCGTGTTGTTGTTGTTTTCGATTTTTGCGGCC	757 th (tie)	1		
VEGFR-2	34,000	GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	4 th	60	90	0.26	
		GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	8 th	29			
		GTCGTGTTGGTTGTTGTTTTCATTTTTGCGGCC	1459 th	1			
3	VEGFR-1	22,093	GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	2 nd	238	351	1.59
			GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	10 th	82		
			GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	42 nd	8		
			GTCGTGTTGGTTGTTGTTTTCATTTTTGCGGCC	72 nd	5		
			GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	103 rd	4		
			GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	278 th (tie)	2		
GTCGTGTTGTTGTTGTTTTCATTTTTGCGGCC	278 th (tie)	2					
GTCGTGTTAATTGTTGTTTTCATTTTTGCGGCC	819 th (tie)	1					

			819 th (tie)	1		
			819 th (tie)	1		
			819 th (tie)	1		
			819 th (tie)	1		
			819 th (tie)	1		
			819 th (tie)	1		
			819 th (tie)	1		
			819 th (tie)	1		
		<hr/>				
			5 th	165		
			7 th	86		
			51 st	5		
			65 th	4		
VEGFR-2	24,684		98 th	3	266	1.07
			824 th (tie)	1		
			824 th (tie)	1		
			824 th (tie)	1		

Table S3. Abundance distribution of Apt02 families (5'-GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGXXX-3') at each round

Selection cycle	target	Number of total reads	Sequence (5' to 3')	Ranking	Counting number	Total counting number	Total abundance ratio (%)
1	VEGFR-1	32,984	Not found	-	ND	ND	ND
	VEGFR-2	52,245	Not found	-	ND	ND	ND
2	VEGFR-1	32,173	GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGCC	23 rd	14	22	0.068
			GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGGCC	38 th	7		
			GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGCC	772 nd	1		
	VEGFR-2	34,000	GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGCC	14 th	18	30	0.088
GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGGCC	16 th	11					
GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGCC	1,014 th	1					
3	VEGFR-1	22,093	GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGCC	22 nd	18	22	0.10
			GCTGATAGGATGGGTTGTAGGTATAGGGGGGGGCC	819 th (tie)	1		
			GCTGATAGGATGGGTTGTAGGTCTAGAGGGGGGCC	819 th (tie)	1		
			GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGGCC	819 th (tie)	1		
	VEGFR-2	24,684	GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGCC	34 th (tie)	7	15	0.061
			GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGGCC	34 th (tie)	7		
			GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGGCC	824 th (tie)	1		
GCTGATAGGATGGGTTGTAGGTCTAGGGGGGGGCC			824 th (tie)	1			




Fig. S1 Schematic of alternating consecutive selection of DNA aptamers using VEGFR-1 and VEGFR-2 immobilized on magnetic beads, referred to as MB1 and MB2, respectively, with deep sequencing analysis.




Fig. S2 SPR sensorgrams used to determine the binding affinities according to single-cycle kinetic analysis.




Fig. S3 SPR sensorgrams of Apt02, Apt02-scr, A35 binding to VEGFR-1.




Fig. S4 *In vitro* tube formation assay using human umbilical vein endothelial cells (HUVECs) on a three-dimensional gel consisting of diluted Matrigel. The cells were treated with Apt01 (20 μ M), Apt02 (20 μ M), A35 (20 μ M) or VEGF165 (20 ng/mL, 0.52 nM). (A) Representative images of tube formation of human umbilical vein endothelial cells (HUVECs) on Matrigel at 4 h. Scale bars are 0.5 mm. (B) Number of mesh in the images of the HUVECs networks at 4 h. (n=3 plots). * $P < 0.05$ as compared to control.




Fig. S5 Inhibition of HUVEC tubule growth by fruquintinib at 5 h. The cells were treated by Apt02 (20 μ M), or VEGF165 (20 ng/mL, 0.52 nM) with or without highly selective small molecule inhibitor of VEGFR tyrosine kinases, fruquintinib (10 μ M). Number of mesh of the HUVECs networks was counted at 5 h. (n=3 plots). * $P < 0.05$ as compared to Apt02-treated group without inhibitor.